Drug Trial Radar · NCT03425474
Study of Remimazolam Tosilate in Patients Undergoing Diagnostic Upper GI Endoscopy
Last checked: Nov 20, 2026Latest source record: Feb 12, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
378
Actual
Start
Sep 1, 2017
Primary completion
Nov 10, 2017
Study completion Nov 10, 2017
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 7, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and efficacy of the sedation for Remimazolam or Propofol in patients undergoing diagnostic upper GI endoscopy.
Conditions
- Sedation
Interventions
Remimazolam TosilateDrug
Initial dose plus supplemental doses as necessary
PropofolDrug
Initial dose plus supplemental doses as necessary
Primary outcomes
What the sponsor says the trial is designed to measure.
- rate of successful sedationTime frame: approximately 3 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Clinical trial Ethnics Committee of Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.